Plasma Protein Biomarker: Diagnosis of Ovarian Cancer

  • There is a great need for a reliable way to diagnose ovarian cancer, especially in the early stages.
  • Analysis of markers in blood offers many advantages in terms of cost and ease of sampling.
  • Researchers at Moffitt Cancer Center have identified a panel of 21 proteins from patient plasma that correlate with ovarian cancer.

FEATURES AND BENEFITS

  • The 21 proteins are differentially expressed in plasma, affording easy sampling from the patient.
  • The panel is based on a large sample size of 160 women, improving reliability of the results.
  • Eight of the proteins are differentially expressed in early stage ovarian cancer, where there is a great need for a reliable test.
  • The protein panel offers promise as a clinical test for diagnosis, screening and monitoring therapy in ovarian cancer.

STAGE OF DEVELOPMENT

An assay is being developed for clinical validation studies.

PUBLICATION/PATENT

Patent application pending.

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent
Haskell.Adler@Moffitt.org
(813) 745-6596

06B098